Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR.
about
A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretionPreventing a Mass Disease: The Case of Gallstones Disease: Role and Competence for Family PhysiciansCombined treatment of somatostatin analogues with pegvisomant in acromegalyGastrointestinal symptoms and motility disorders in patients with systemic sclerodermaClinical Use of Cinacalcet in MEN1 HyperparathyroidismGallstone disease.Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients.Octreotide LAR: safety and tolerability issues.Octreotide long-acting repeatable for acromegaly.Roles of cholesterol and bile salts in the pathogenesis of gallbladder hypomotility and inflammation: cholecystitis is not caused by cystic duct obstruction.Adverse events associated with somatostatin analogs in acromegaly.Management of gallstones and its related complications.Dumping syndrome after esophageal, gastric or bariatric surgery: pathophysiology, diagnosis, and management.Telocytes: New Players in Gallstone Disease.Octreotide therapy in dumping syndrome: Analysis of long-term results.Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems.Incidence of gall stone formation in acromegalic patients on octreotide therapy.The uncovering and characterization of a CCKoma syndrome in enteropancreatic neuroendocrine tumor patients.Octreotide increases the proportions of arachidonic acid-rich phospholipids in gall-bladder bile.Functions of the Gallbladder.Physiology and Pathophysiology of the Biliary Tract: The Gallbladder and Sphincter of Oddi—A Review
P2860
Q24678786-0FF04274-7B7F-4BC2-A4CE-9255BE69C599Q26741095-B00316AF-3A39-4CD9-BC78-4E7F3452372EQ26776366-B6EC0A16-EB7D-4961-A24D-E4D7E4FFA392Q33321445-0B95CAF3-6F5D-4C9E-BDDA-40A55BA4FEAAQ33879558-932932C3-BFF8-475C-8539-B9F722D907AFQ34634193-A36B1990-BF8B-4341-88A3-99EF837039FAQ37292997-6B693BEB-5A9B-433F-8C73-F0595820B274Q37649647-B2338DB1-64DB-4B5A-95EE-2AFA7147CC41Q37990556-F75A78E6-173C-4BBB-B49A-FE1BFC152574Q38081990-4961338F-BB7B-4A7A-9F89-DAA6FDCA7D4BQ38548973-1AE90881-65E0-4980-B610-500B439CA3AFQ38631199-06E9D317-2CF6-4A0C-99DC-AD8AF57A9894Q38982987-EC7B8A62-B101-47F5-A8B8-6981E3609849Q38994820-9E2B1CE1-8886-4343-9885-03ED6DC07C12Q39344385-95B8BA8D-AB32-4506-A081-B9DFF6E6B222Q40229787-E0EDD459-2A2E-4B4C-BB3A-94B48838A9B1Q42174145-E7934A60-71F9-44D1-87D2-ADCEB6EF6C19Q42493305-0BABE141-C4E0-49E3-B64D-578AF9E2C8CDQ43734581-C032F726-28E6-4711-BEC2-01E554CF6DB5Q50163355-F8E97C60-7325-4533-9837-0B2163428AAEQ58999764-6D30A872-B83C-4517-923F-88011841E819
P2860
Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Severe impairment of postprand ...... tients during Sandostatin LAR.
@en
Severe impairment of postprand ...... tients during Sandostatin LAR.
@nl
type
label
Severe impairment of postprand ...... tients during Sandostatin LAR.
@en
Severe impairment of postprand ...... tients during Sandostatin LAR.
@nl
prefLabel
Severe impairment of postprand ...... tients during Sandostatin LAR.
@en
Severe impairment of postprand ...... tients during Sandostatin LAR.
@nl
P2093
P2860
P1476
Severe impairment of postprand ...... tients during Sandostatin LAR.
@en
P2093
Koppeschaar HP
Moschetta A
Rehfeld JF
Van Erpecum KJ
Vanberge-Henegouwen GP
P2860
P304
P356
10.1046/J.1365-2036.2001.00924.X
P407
P577
2001-02-01T00:00:00Z